Source: Annual Congress 2009 - Cystic fibrosis: disease progression and novel therapies
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Kerem, S. Bauer, P. Strauss, N. Jaffe, S. Armoni, T. Pugatsch, D. Shoseyov, N. Tov (Jerusalem, Rehovot, Israel). Safety and efficacy of inhaled human α-1 antitrypsin (AAT) in cystic fibrosis: a report of a phase II clinical study. Eur Respir J 2009; 34: Suppl. 53, 1624

Member's Comments

No comment yet.

Related content which might interest you: Safety and tolerability of aerosolized human alpha-1 antitrypsin (AAT): a phase Ia/Ib clinical study Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD II Year: 2008 Efficacy and safety of inhaled ENaC inhibitor BI 1265162 in patients with cystic fibrosis: BALANCE-CF 1, a randomised, phase II study Source: Eur Respir J, 59 (2) 2100746; 10.1183/13993003.00746-2021 Year: 2022 Therapeutic efficacy of alpha-1 antitrypsin (AAT) augmentation therapy on the loss of lung tissue: an integrated analysis Source: Annual Congress 2008 - Recent advances in the pathogenesis and treatment of asthma and COPD Year: 2008 All-case post-marketing surveillance (PMS) of pirfenidone in Japan: Clinical characteristics, efficacy and safety profile in >1300 patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Regional deposition of 99mTc-labelled alpha-1 antitrypsin (AAT) in patients with alpha-1 antitrypsin deficiency and cystic fibrosis (CF) compared with healthy volunteers Source: Annual Congress 2007 - Cystic fibrosis: the balance between treatment and side-effects Year: 2007 Safety and efficacy of intravenous (IV) Fosfomycin in adult cystic fibrosis patients Source: International Congress 2018 – Latest developments in cystic fibrosis Year: 2018 Late Breaking Abstract - Effectiveness and tolerability of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) from a large Italian practice cohort Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias Year: 2018 Association between alpha1 antitrypsin (AAT) circulating polymers (CP) and lung and liver disease in patients with AAT deficiency (AATD). Source: Virtual Congress 2021 – Molecular pathology and cell biology of pulmonary diseases Year: 2021 Efficacy and safety of abediterol (LAS100977) in stable asthma: Phase II, randomized, crossover study Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Real-life data on the safety and tolerability of Pirfenidone versus Nintedanib in Idiopathic Pulmonary Fibrosis (IPF) patients: A single-centre retrospective study Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 SAR156597 in idiopathic pulmonary fibrosis: a phase 2 placebo-controlled study (DRI11772) Source: Eur Respir J, 52 (6) 1801130; 10.1183/13993003.01130-2018 Year: 2018 Exploratory analysis of phase III trial of pirfenidone: Most effective population in patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2010 - New insights in the treatment of idiopathic pulmonary fibrosis Year: 2010 Recombinant human pentraxin-2 therapy in patients with idiopathic pulmonary fibrosis: safety, pharmacokinetics and exploratory efficacy Source: Eur Respir J 2016; 47: 889-897 Year: 2016 Recombinant human pentraxin-2 for idiopathic pulmonary fibrosis: Design of STARSCAPE-OLE, a Phase III open label extension study Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 Efficacy and safety of abediterol (LAS100977) in patients with COPD: Phase II, randomised, crossover study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 The results of alpha-1 antitrypsine (AAT) phenotyping in patients with COPD Source: Eur Respir J 2002; 20: Suppl. 38, 260s Year: 2002 Fatigue in patients with idiopathic pulmonary fibrosis (IPF) from the pooled pirfenidone (PFD) Phase III trials Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 Abediterol in stable asthma:efficacy, safety and tolerability results from a Phase II, randomised, crossover study Source: International Congress 2014 – Asthma and COPD management Year: 2014 Effects of double dose alpha 1 antitrypsin (AAT) therapy on cytokine pathways in AAT Deficiency (AATD) Source: International Congress 2018 – COPD phenotypes: a1 antitrypsin deficiency and beyond Year: 2018